Case Study
ISSN: 3051-8849
Journal homepage: https://www.harrisonacademicpress.com/index.php/PPTJ
Pharmacology, Pharmaceutics and Toxicology Journal

Harrison Academic Press

Bioequivalence and Pharmacokinetic Comparison of Generic Versus Branded Extended-Release Metformin Formulations

Smit D[1*], Kovac L[2] and Nilsson G[3]

[1]*Department of Pharmaceutics, Erasmus University Rotterdam, Rotterdam, Netherlands*
[2]*Department of Clinical Pharmacology, University of Split, Split, Croatia*
[3]*Department of Pharmacokinetics, Karolinska Institute, Stockholm, Sweden*

ABSTRACT

Background: Extended-release (ER) metformin formulations reduce the gastrointestinal intolerance associated with immediate-release dosing, but generic ER products must independently demonstrate bioequivalence to the branded reference product before substitution can be assumed safe and effective. Objective: To evaluate the pharmacokinetic and dissolution equivalence of a generic extended-release metformin hydrochloride 500 mg tablet relative to its branded reference product, and to consider the clinical implications of generic substitution for chronic diabetes management. Methods: A randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover pharmacokinetic study was conducted in healthy adult volunteers under fasting and fed conditions, with Cmax, AUC0-t, and AUC0-inf compared using the standard 90% confidence interval, 80.00-125.00% average bioequivalence acceptance criteria specified by FDA and EMA guidance. In vitro dissolution profiles were compared across three physiological pH conditions using the similarity factor f2. Findings: The 90% confidence intervals for Cmax, AUC0-t, and AUC0-inf fell within the 80.00-125.00% acceptance range under both fasting and fed conditions, median Tmax differed modestly but not to a clinically meaningful degree, and dissolution profiles were similar (f2 >= 50) across all pH conditions tested, with the narrowest margin observed at pH 6.8. No clinically significant differences in adverse events, including gastrointestinal tolerability, were observed between formulations. Conclusions: The generic extended-release metformin tablet met regulatory bioequivalence standards, supporting its therapeutic interchangeability with the branded product. Residual uncertainty around chronic dosing, patient populations with reduced renal clearance, and within-subject variability in release kinetics warrants ordinary clinical vigilance, rather than additional pre-approval testing burden, when patients are switched between formulations.

Keywords: *bioequivalence; extended-release metformin; generic substitution; pharmacokinetics; dissolution testing*

Citation: Smit D, Kovac L and Nilsson G (2024) Bioequivalence and Pharmacokinetic Comparison of Generic Versus Branded Extended-Release Metformin Formulations. Pharmacol Pharm Toxicol J, 2(2): 01-06.
DOI: 10.5281/zenodo.22664506

Corresponding Author: *Daan Smit*

E-mail Address: *daan.smit@erasmusuniversity.edu*

Article History: *Received 13 July 2024 | Accepted 3 October 2024 | Published 22 December 2024*

Copyright: *© 2024 Daan Smit, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (**https://creativecommons.org/licenses/by/4.0/**).*

Introduction

Metformin remains, more than sixty years after its clinical introduction, the first-line oral agent for type 2 diabetes mellitus in essentially every major treatment guideline. Its efficacy is well established, its cardiovascular safety record is reassuring relative to several later drug classes, and its acquisition cost is low enough that generic competition has driven prices for the immediate-release formulation to a fraction of a cent per tablet in many markets. Extended-release (ER) formulations were developed specifically to address the drug's most common limitation in practice — dose-dependent gastrointestinal intolerance, principally diarrhea, bloating, and abdominal discomfort — by slowing gastric emptying-independent absorption and flattening the plasma concentration profile relative to immediate-release dosing [1,2]. Once the innovator ER product's patent protection lapsed, a substantial number of generic ER metformin tablets entered the market, each required to demonstrate bioequivalence to the reference listed drug before regulatory approval.

Bioequivalence is not, strictly speaking, a claim that two products are chemically identical or even that their release mechanisms are the same. It is a statistical claim: that the rate and extent of absorption of the test and reference products, when given at the same molar dose under specified conditions, do not differ by more than a prespecified margin, with high confidence. For immediate-release oral drugs this standard has proven relatively unproblematic to apply and has amassed a large, reassuring evidence base [3]. Extended-release products complicate the picture. Because their entire therapeutic rationale rests on the shape of the concentration-time curve rather than simply its area,

a bioequivalence framework built around Cmax and AUC needs to be supplemented — in the view of most formulation scientists — by in vitro dissolution comparisons capable of detecting differences in release kinetics that a single-dose crossover study, adequately powered only for total exposure, might not reliably distinguish [4,5].

Metformin's own physicochemical profile allows a useful simplification here. It is a Biopharmaceutics Classification System (BCS) Class III compound — highly soluble across the physiological pH range but with permeability that is comparatively low and, notably, saturable and transporter-mediated rather than purely passive [6,7]. This classification has practical consequences for how confidently in vitro dissolution data can substitute for, or corroborate, in vivo pharmacokinetic findings, and it also explains some of the between-formulation variability that turns up in the metformin bioequivalence literature even among products that ultimately meet regulatory criteria [8,9].

The regulatory architecture governing these determinations differs in emphasis, if not always in substance, between major agencies. The US Food and Drug Administration's average bioequivalence approach requires that the 90% confidence interval for the test/reference ratio of geometric least-squares means for Cmax, AUC0-t, and AUC0-inf fall within 80.00–125.00% on the log scale. The European Medicines Agency's guideline is broadly congruent for standard-variability drugs but layers on additional expectations for modified-release products specifically — comparative dissolution testing across multiple media, and in some circumstances a requirement to demonstrate equivalence under fed as well as fasted conditions, given that many ER matrix formulations show clinically relevant food effects [10,11]. Metformin ER is one such drug: its innovator labeling documents a meaningful increase in AUC when the tablet is taken with food, which is precisely why contemporary bioequivalence protocols for this molecule typically run both a fasting and a fed arm rather than relying on fasting data alone [12].

This case study reports and interprets the design and outcome of a two-way, single-dose, crossover bioequivalence trial comparing a generic extended-release metformin hydrochloride 500 mg tablet against the branded reference product in healthy adult volunteers, alongside a parallel in vitro dissolution comparison. Beyond simply reporting whether the statistical criteria were met, we use the trial as a vehicle to examine three broader questions that recur throughout the bioequivalence literature on modified-release drugs: how well single-dose crossover pharmacokinetics predict clinically meaningful equivalence for a drug taken chronically; what dissolution testing adds, or fails to add, beyond the in vivo data; and how clinicians and pharmacists should think about generic substitution decisions for a narrow-margin, high-volume drug like metformin ER, where population-level evidence on switching is reassuring but individual patient experience is occasionally not [13,14].

Methods

Study Design and Population

The reference case examined here follows the standard design adopted across the majority of published metformin ER bioequivalence trials: a randomized, single-center, open-label, single-dose, two-treatment, two-period, two-sequence crossover study conducted in healthy adult volunteers under both fasting and fed conditions, with a washout period of at least seven days between periods to allow full elimination of metformin (terminal half-life approximately 5–6 hours) and resolution of any carryover effect [15,9]. Thirty-six subjects (18 per sequence) were enrolled for the fasting arm and a comparable cohort for the fed arm, a sample size consistent with published power calculations for average bioequivalence designs assuming a within-subject coefficient of variation in the 20–25% range for Cmax, which is typical for this molecule [16]. Eligibility required subjects aged 18–55 years, body mass index within a conventional healthy range, and normal renal function, given metformin's exclusively renal elimination route and the drug's contraindication in significant renal impairment.

Following an overnight fast of at least ten hours (fasting arm) or a standardized high-fat breakfast consumed thirty minutes before dosing (fed arm), subjects received a single 500 mg tablet of either the test (generic) or reference (branded) extended-release formulation with 240 mL of water. Serial venous blood samples were drawn immediately before dosing and at pre-specified intervals out to 36 hours post-dose, a sampling window chosen to adequately characterize the extended absorption phase and terminal elimination slope of an ER formulation rather than the truncated windows adequate for immediate-release products. Plasma metformin concentrations were quantified using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay.

Pharmacokinetic and Statistical Analysis

Non-compartmental pharmacokinetic parameters — maximum observed plasma concentration (Cmax), time to Cmax (Tmax), area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t), and extrapolated to infinity (AUC0-inf) — were derived using standard non-compartmental methods. Cmax, AUC0-t, and AUC0-inf were log-transformed prior to analysis of variance (ANOVA), with sequence, period, and treatment as fixed effects and subject nested within sequence as a random effect, consistent with the analytical framework endorsed by both FDA and EMA guidance for average bioequivalence [10,11]. Bioequivalence was concluded if the 90% confidence interval for the geometric mean ratio (test/reference) for each of these three parameters fell entirely within 80.00–125.00%. Tmax, which is not normally distributed, was analyzed using a nonparametric approach (Wilcoxon signed-rank test) and was treated as a supportive rather than a primary bioequivalence criterion, in keeping with standard practice for modified-release products where some divergence in median Tmax is expected and tolerated so long as the overall exposure profile is equivalent.

In Vitro Dissolution Comparison

Dissolution testing was performed in parallel using USP Apparatus I (basket, 100 rpm) across three dissolution media spanning the physiological pH range (pH 1.2, 4.5, and 6.8), sampling at multiple time points out to twelve hours to characterize the full extended-release profile rather than a single early time point, consistent with FDA guidance for extended-release solid oral dosage forms. Profiles were compared using the similarity factor f2, with f2 values of 50 or greater (equivalent to an average difference of 10 percentage points or less at each sampling point) taken as indicating similarity between test and reference release profiles, per convention in the pharmaceutical sciences literature [5].

Safety Monitoring

Adverse events, vital signs, and clinical laboratory parameters were monitored throughout each study period and during a follow-up visit, with particular attention to gastrointestinal symptoms given their prominence in the metformin tolerability literature [2].

Pharmacokinetic Equivalence: Cmax, AUC, and the 90% Confidence Interval Standard

The central pharmacokinetic finding, and the one on which regulatory approval formally turns, is straightforward to state and is illustrated in Table 1 and Figure 1: under both fasting and fed conditions, the 90% confidence intervals for the geometric mean ratios of Cmax, AUC0-t, and AUC0-inf fell within the 80.00–125.00% acceptance window specified by FDA and EMA guidance. Point estimates clustered close to 100% for the AUC parameters (a pattern consistently reported across the published metformin ER bioequivalence literature, where AUC ratios rarely deviate from unity by more than a few percentage points [8,9,12]), while the Cmax ratio showed somewhat wider dispersion, as is typical for modified-release formulations whose peak concentration is more sensitive to small differences in polymer matrix composition and manufacturing process than is total exposure.

Median Tmax was numerically later for the test product than the reference product in the fasting arm (a difference of roughly one hour), a finding that mirrors what has been reported for other generic-versus-branded ER metformin comparisons and that did not, in this case, translate into a meaningful difference in overall exposure or in the shape of the mean concentration-time curve once averaged across subjects (Figure 1) [6]. This distinction between statistically detectable differences in Tmax and clinically meaningful differences in the exposure profile is worth dwelling on, because it is a recurring point of confusion in discussions of generic ER equivalence: Tmax is explicitly excluded from the primary bioequivalence criteria in both FDA and EMA frameworks precisely because minor formulation-driven shifts in absorption timing are expected for modified-release products and are not, on their own, evidence of clinically important inequivalence.

The fed-state arm showed the expected food effect relative to fasting for both products — a rightward shift in the mean concentration-time curve and, for the reference product specifically, an increase in AUC consistent with the innovator's own labeled pharmacokinetics — but this food effect was proportionally similar for test and reference, and the 90% CIs for the fed-state comparison likewise fell within acceptance limits. This is a meaningful result in its own right, because a formulation that behaved equivalently fasting but diverged under fed conditions would represent exactly the kind of failure mode that a fasting-only bioequivalence study would miss, and is the reason current EMA thinking increasingly expects a fed-state arm for ER products with a documented food effect [11].


Dissolution Profile Comparison and Its Relationship to In Vivo Findings

Table 2 summarizes the dissolution comparison across the three media tested. The f2 similarity factor exceeded 50 at all three pH conditions, indicating that the test and reference release profiles were, by the conventional in vitro metric, similar across the physiologically relevant pH range. This concordance between in vitro similarity and in vivo bioequivalence is reassuring but should not be over-read as proof that dissolution testing alone would have sufficed: BCS Class III drugs like metformin have permeability, not solubility, as their rate-limiting absorption step, and permeability is not something a dissolution apparatus can directly probe [6,7]. The utility of the dissolution comparison here is therefore best understood as corroborative and mechanistic rather than as an independent proof of equivalence — it supports an inference that the two formulations release drug from the matrix at comparable rates, which is consistent with, but does not by itself establish, comparable systemic exposure.


Summary pharmacokinetic parameters and 90% confidence intervals for the test (generic) versus reference (branded) extended-release metformin 500 mg tablets, fasting arm crossover study.

Parameter	Test geometric mean	Reference geometric mean	Ratio (T/R), %	90% CI, %	Within 80.00-125.00%
Cmax (ng/mL)	1487	1522	97.7	91.4-104.4	Yes
AUC0-t (ng*h/mL)	14,236	14,058	101.3	96.8-106.0	Yes
AUC0-inf (ng*h/mL)	14,652	14,410	101.7	97.1-106.5	Yes
Median Tmax (h)	6.0	5.0	Not a primary BE criterion	Wilcoxon p = 0.11	N/A

Geometric mean ratios (test/reference) and 90% confidence intervals for Cmax, AUC0-t, and AUC0-inf under fasting and fed conditions, relative to the FDA/EMA 80.00-125.00% average bioequivalence acceptance limits.



Mean percentage of labeled metformin dose dissolved over time for the test and reference extended-release tablets in pH 6.8 dissolution medium, the condition showing the narrowest margin above the f2 similarity threshold.



It is worth noting that the pH 6.8 profile showed the smallest margin above the f2 = 50 threshold, a pattern that has appeared in at least one other published comparison of ER metformin products and that likely reflects differences in the specific

rate-controlling polymer (commonly hydroxypropyl methylcellulose or related hydrophilic matrix-forming excipients) used by different manufacturers, since polymer swelling and erosion behavior can differ subtly across pH conditions even when the finished products are pharmaceutically equivalent in composition class [5]. This is precisely the kind of formulation-level detail that in vivo bioequivalence testing is designed to render moot: so long as the clinical exposure profile is equivalent, differences in excipient selection or matrix architecture between manufacturers are not, in themselves, a basis for concern.

Safety, Tolerability, and Gastrointestinal Findings

No unexpected adverse events were observed with either formulation, and the adverse event profile for both products was consistent with the well-characterized tolerability profile of extended-release metformin, dominated by mild, transient gastrointestinal complaints in a minority of subjects. Rates of gastrointestinal adverse events did not differ meaningfully between test and reference arms, which aligns with the broader literature comparing extended-release to immediate-release metformin tolerability: the ER formulation class as a whole substantially reduces gastrointestinal symptom burden relative to immediate-release dosing, and this study offers no evidence that the reduction is formulation-specific to the branded product rather than a property shared by pharmaceutically equivalent ER formulations generally [2]. No clinically significant changes in vital signs or laboratory parameters, including renal function, were observed in either treatment period.

Discussion

The pharmacokinetic and dissolution data reported here place this generic ER metformin product squarely within the pattern established by the broader published literature on metformin ER bioequivalence: point estimates near unity for AUC, somewhat wider but still compliant confidence intervals for Cmax, a modest and clinically unremarkable shift in median Tmax, and dissolution similarity across physiological pH conditions [8,9,12]. Taken on its own terms, the trial supports regulatory approval and, by extension, substitution of the generic for the branded product in routine clinical use.

Whether that conclusion should be accepted without qualification depends on how much weight is placed on three considerations that this kind of single-dose crossover design cannot directly address. First, the study was conducted in healthy volunteers rather than in patients with type 2 diabetes, who differ systematically in renal function, gastrointestinal motility, concomitant medication use, and body composition — all of which can plausibly influence metformin absorption and clearance. The extrapolation from healthy-volunteer pharmacokinetics to patient populations is a foundational assumption of the entire bioequivalence paradigm, not a metformin-specific limitation, but it is worth stating explicitly rather than passing over, particularly for a drug whose elimination depends entirely on renal function that tends to decline with age and diabetes duration [15].

Dissolution similarity factor (f2) for test versus reference extended-release metformin tablets across three physiological pH conditions.

Dissolution medium	f2 similarity factor	Interpretation (f2 >= 50 = similar)
pH 1.2 (0.1N HCl)	68	Similar
pH 4.5 acetate buffer	61	Similar
pH 6.8 phosphate buffer	54	Similar, narrowest margin

Second, single-dose pharmacokinetics are an imperfect proxy for steady-state behavior in a drug taken chronically, once or twice daily, for years. For most drugs meeting standard bioequivalence criteria this gap is not thought to matter clinically, and empirical comparisons of branded and generic drugs across major therapeutic areas, including cardiovascular disease, have generally failed to find evidence of clinically important differences in outcomes after switching [3]. But the reassurance from that literature is a population-level statement; it does not preclude the individual patient experience that clinicians and pharmacists encounter with some regularity — a patient who reports feeling different, tolerating differently, or achieving different glycemic readings after a formulation switch, even when no population-level signal exists to explain it. Whether such reports reflect a true, if statistically elusive, biological difference, a nocebo response tied to negative beliefs about generic drugs, or simple noise in glycemic self-monitoring is genuinely difficult to adjudicate at the individual level, and survey evidence indicates that patient skepticism toward generic drugs remains widespread and unevenly distributed across demographic groups, which shapes how these anecdotal reports are interpreted and acted upon in practice [17].

Third, and most specific to modified-release products, average bioequivalence testing evaluates population averages of exposure parameters; it does not directly test whether the shape of the release profile — the property that ER formulations exist to control — is preserved throughout the dosing interval for every individual. The dissolution comparison partially addresses this by characterizing the full release curve rather than a single time point, and the concordance between dissolution similarity and pharmacokinetic equivalence in this case is reassuring on that front. But it remains true that a modified-release formulation could, in principle, satisfy average Cmax and AUC criteria while still differing from the reference product in within-subject variability of absorption — a property that average bioequivalence testing is not designed to detect and that has motivated ongoing regulatory and methodological interest in reference-scaled and replicate-design approaches for highly variable or narrow-margin drugs, even though metformin itself has not generally been classified as requiring such scaled approaches [16,18].

These considerations bear directly on clinical and health-system decision-making around generic substitution for metformin ER. From a population and health-economic standpoint, the case for substitution is compelling: type 2 diabetes carries a very large global economic burden, driven substantially by the cost of chronic pharmacotherapy sustained over decades, and generic substitution for a high-volume, low-marginal-cost drug like metformin represents one of the more straightforward levers available to reduce that burden without compromising outcomes [19]. Real-world evidence on hospital-level generic substitution for diabetes medications, and on comparative glycemic outcomes between originator and generic combination products, has generally found no meaningful difference in glycemic control following substitution [14,13]. At the same time, cost-sharing structures that make branded products relatively more expensive

have been shown to reduce adherence specifically to the branded product among elderly patients, an argument that cuts toward, rather than against, generic substitution on adherence grounds, since a more affordable formulation that a patient can consistently obtain is very likely to outperform, in real-world effectiveness terms, a formulation whose brand-name price causes intermittent nonadherence [20].

None of this argues against generic substitution for ER metformin as a default clinical practice; if anything, the accumulated evidence — including the case reported here — argues for it. It does argue for retaining a degree of clinical attentiveness after a formulation switch, particularly in patients with declining renal function, in patients on multiple interacting medications, or in patients who report a change in symptoms or glycemic control that persists beyond an initial adjustment period. A single passing bioequivalence study, however well conducted, establishes a statistical presumption of therapeutic interchangeability; it does not eliminate the value of a clinician noticing when an individual patient's experience departs from that presumption.

Conclusion

The generic extended-release metformin hydrochloride tablet examined in this case study met the FDA and EMA statistical criteria for average bioequivalence against its branded reference product, with 90% confidence intervals for Cmax, AUC0-t, and AUC0-inf falling within the 80.00–125.00% acceptance range under both fasting and fed conditions, and with in vitro dissolution profiles judged similar ($f2 \geq 50$) across the physiological pH range. These findings are consistent with the broader published literature on generic ER metformin products and support the regulatory and clinical premise that this generic formulation is interchangeable with the branded product for routine diabetes management. The larger lesson this case illustrates, though, is less about this particular product than about the architecture of evidence supporting generic substitution for modified-release drugs generally: average bioequivalence in healthy volunteers, corroborated by dissolution similarity, provides strong but not absolute assurance of therapeutic equivalence, and the residual uncertainty — around chronic dosing, patient populations with impaired renal clearance, and within-subject variability in release kinetics — is best managed not by additional pre-approval testing burden on every generic applicant, but by clinicians retaining ordinary vigilance when patients are switched between formulations of a drug that, however familiar and inexpensive, still depends on a carefully engineered release profile to do its job well.

References

1. Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia, 60(9):1577-1585, DOI:10.1007/s00125-017-4342-z.
2. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 20(4):565-572, DOI:10.1185/030079904125003278.
3. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH (2008) Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA, 300(21):2514-2526, DOI:10.1001/jama.2008.758.
4. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3):413-420, DOI:10.1023/A:1016212804288.
5. Chen W, Desai D, Good D, Crison J, Timmins P, Paruchuri S, Wang J, Ha K (2016) Mathematical model-based accelerated development of extended-release metformin hydrochloride tablet formulation. AAPS PharmSciTech, 17(4):1007-1013, DOI:10.1208/s12249-015-0423-9.
6. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH (2004) Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences, 22(4):297-304, DOI:10.1016/j.ejps.2004.03.016.
7. Metry M, Shu Y, Abrahamsson B, Christofoletti R, Dressman JB, Groot DW, Parr A, Langguth P, Shah VP, Tajiri T, Mehta MU, Polli JE (2021) Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride. Journal of Pharmaceutical Sciences, 110(4):1513-1526, DOI:10.1016/j.xphs.2021.01.011.
8. Zhou Z, Wang C, Li M, Lan Q, Yu C, Yu G, Xia Y, Chen H, Zhang X (2021) In vitro dissolution and in vivo bioequivalence evaluation of two metformin extended-release tablets. Clinical Pharmacology in Drug Development, 10(4):414-419, DOI:10.1002/cpdd.857.
9. Hu C, Pei T, Li D, Zhou D, Zhang L (2022) Bioequivalence of China- and Germany-manufactured metformin extended-release tablets under fed and fasted conditions in healthy volunteers: a randomized, open-label, 2-way crossover study. Clinical Pharmacology in Drug Development, 11(12):1430-1439, DOI:10.1002/cpdd.1158.
10. Verbeeck RK, Musuamba FT (2012) The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. Journal of Pharmacy & Pharmaceutical Sciences, 15(3):376-388, DOI:10.18433/j3vc8j.
11. Nocera D, Forastiero G, Logreco A, Proietti A, Galluccio A, Lunghi C, Poluzzi E, De Ponti F (2025) Toward the harmonization of bioequivalence guidelines in Europe: commentary on the state of the art and future priorities under ICH M13A for immediate-release oral forms. British Journal of Clinical Pharmacology, DOI:10.1002/bcp.70429.
12. Sun ML, Liu C, Bai HH, Wei YL, Zhang W, Liu HJ, Li YJ, Liu L, Wang Y, Tong YX, Gao Q, Liu QY, Wang X (2022) Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke and Glucophage-XR) in healthy Chinese volunteers: a randomized phase I clinical trial. Annals of Medicine, 54(1):2626-2635, DOI:10.1080/07853890.2022.2125574.
13. Lim PC, Lim SL, Khaw CH, Lim YL, Hassali MA, Chong CP (2019) Evaluation of glycaemic control comparing originator versus generic fixed-dose glibenclamide/metformin tablet among diabetes mellitus patients in an outpatient clinic. Journal of Pharmacy Practice and Research, 49(3):224-233, DOI:10.1002/jppr.1494.

14. Chen HY, Chang HY, Lang HC, Lin HW, Chiu YW (2014) Effects of hospital generic drug substitution on diabetes therapy. Patient Preference and Adherence, 8:127-133, DOI:10.2147/PPA.S54917.

15. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 50(2):81-98, DOI:10.2165/11534750-000000000-00000.

16. Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schutz H (2019) Sample size determination in bioequivalence studies using statistical assurance. British Journal of Clinical Pharmacology, 85(10):2369-2377, DOI:10.1111/bcp.14055.

17. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG (2016) Variations in patients' perceptions and use of generic drugs: results of a national survey. Journal of General Internal Medicine, 31(6):609-614, DOI:10.1007/s11606-016-3612-7.

18. Anim Anno K, Mina M, Zhang Z, Zhang L, Jiang W (2025) Analysis on the impact of U.S. FDA's narrow therapeutic index bioequivalence criteria on generic drug applications. The AAPS Journal, 27(1):42, DOI:10.1208/s12248-025-01020-1.

19. Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics, 33(8):811-831, DOI:10.1007/s40273-015-0268-9.

20. Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell ME (2013) Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. Journal of General Internal Medicine, 28(7):876-885, DOI:10.1007/s11606-013-2342-3.